Headlines about Tenax Therapeutics (NASDAQ:TENX) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Tenax Therapeutics earned a news impact score of 0.08 on Accern’s scale. Accern also gave media headlines about the specialty pharmaceutical company an impact score of 45.1317442659826 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Shares of Tenax Therapeutics (TENX) traded up 34.1579% on Friday, reaching $0.5098. 6,607,459 shares of the company traded hands. The stock’s market cap is $14.39 million. Tenax Therapeutics has a 52-week low of $0.31 and a 52-week high of $2.65. The stock has a 50 day moving average of $0.36 and a 200 day moving average of $0.49.

TRADEMARK VIOLATION NOTICE: “Tenax Therapeutics (TENX) Earns Daily News Impact Score of 0.08” was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.watchlistnews.com/tenax-therapeutics-tenx-earns-daily-news-impact-score-of-0-08/1618169.html.

About Tenax Therapeutics

Tenax Therapeutics, Inc is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products for the critical care market. The Company’s main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure.

Insider Buying and Selling by Quarter for Tenax Therapeutics (NASDAQ:TENX)

Receive News & Ratings for Tenax Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.